Today, there are an increasing number of small- and medium-sized R&D companies coming to the island, and Fortune 100 companies using the services of smaller local…
In Conversation
We do not have the strength to compete with traditional players, so being digitally disruptive is our key asset
Cell culture technology is the core for bio-manufacturing, not only recombinant proteins but any biologicals, including vaccines as well as gene and cell therapies!
Our goal was to revolutionize the way chronic illness is managed and create a modern solution using today’s technology
Looking at our portfolio mix and our operations, we can see that the biotech boom in China is really driving demand for new solutions
We are at the epicentre of cell and gene therapy, what we are calling ‘Cellicon Valley’. Nowhere else boasts such a concentration of cell and gene…
Through close collaboration with KOLs and medical doctors, we will continue to explore the different ways to utilize cell treatment therapy
Over the past five years, drug expenditures per capita have actually declined, while overall healthcare expenses per capita have increased by 30 percent
AI is the future of the industry that has all the potential to transform and combat the complex drug discovery process.
We came up with the concept of digitizing the best treatment practices and putting them online to reach more patients
It is important we continue efforts to streamline our local processes to maximize all the potential France has and to bring more clinical trials to patients
The most important factor in Taiwan’s biotech environment is talent
